Welcome to BioSeeker Group!

Triple Target Atlas in Oncology Drug Development

Additional Information

Published on Date Multi-report (See individual release dates)
Format PDF
Publisher BioSeeker Group

Availability: In stock

$3,450.00

Quick Overview

This report is an open landscape of resources to build, fuel, and drive your scientific competitive vehicle for the advancement of cancer drugs. It will assist you in lead commercial analysis and product strategy thinking to build and nurture current and future portfolio of drug candidates and R&D alliances.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Target Atlas in Oncology Drug Development.

    To find out more about Triple Target Atlas in Oncology Drug Development, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Target Atlas in Oncology Drug Development is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

With the emergence of new technologies and an increased understanding of the biological basis for cancer evolution, the molecular changes that distinguish malignant-cells from normal cells are becoming increasingly apparent, offering a growing range of potential drug targets in the form of altered genes, proteins or corrupted pathways. Drug targets are the critical link between drugs and their role in the treatment of medical disorders.

This report, Triple Target Atlas in Oncology Drug Development, is written for you to identify your competition and understand which targeting strategies are at work within the cancer drug development landscape. It allows you to pin-point which competitors drugs’ clinical out-come may have bearing on your own drug development and who are developing sequels to successful drugs. This report also helps you to locate white-spots in the competitive landscape, giving you little or no competition. Conversely it may reveal unexpected competition for you.

Triple Target Atlas in Oncology Drug Development is a triple report where you may select any three reports from a total of nine different and independent target reports covering five different targeted therapies areas and four major tumor types in detail:

Targeted Therapy Strategies in Cancer

 Major Tumor Types

 

Each report subject (click on each subject for detailed information) covers:

  • Compound strategies based on sub-cellular localization of cancer drug targets
  • The Cancer Genome Project and cancer drug targets
  • Expression levels of identified drug targets in selected tumor type
  • Pathway analysis of cancer drug targets
  • Target-target interactions among identified cancer targets
  • Structure-based drug design in s stimulated by available structure data on biological targets
  • Unique, in-depth, drug target validating profiles, highlighting twelve themes about the drug target, i.e. protein-protein interaction with other cancer drug targets, pursued cancer indications, drugs under development, presence in the Cancer Genome Project etc.
  • Drug-target interactome
  • The progression and maturity of cancer targets: New and unique cancer drug targets
  • Indication specific reports deal with targets by R&D approach in specified cancer types, whereas targeted therapy specific reports deal with targets by cancer indication.
  • Cancer drug target profiles by investigator

This report is an open landscape of resources to build, fuel, and drive your scientific competitive vehicle for the advancement of cancer drugs. It will assist you in lead commercial analysis and product strategy thinking to build and nurture current and future portfolio of drug candidates and R&D alliances. This report will help you to streamline your analysis of new as well as of established drug targets, when looking for clinical proofs, indication selection, competitive environment etc.

To order a Triple Target Atlas in Oncology Drug Development report just indicate any three subjects from above list in the message field of the order.

Alternative Versions of this Report:

  • Complete Target Atlas in Oncology Drug Development: From Tumor to Targeted Therapy
  • Target Atlas in Oncology Drug Development: Major Tumor Types
  • Target Atlas in Oncology Drug Development: Targeted Therapies

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Target Atlas in Oncology Drug Development.
    To find out more about Triple Target Atlas in Oncology Drug Development, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Target Atlas in Oncology Drug Development is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Oncology' category:


Chemokine Signaling Pathway in Cancer Drug Pipeline Update
BioSeeker Group have identified 232 companies plus partners who are today developing 323 chemokine signaling pathway targeting drugs in 1189 developmental projects in cancer across 177 different targets. In addition, there are 3 suspended drugs and another 127 drugs where development has been ceased. Learn More


Commercializing Breast Cancer Drugs: The Faster Route to Consider Your Options and Position of Others
This report represents a new and unique way of stratifying and analyzing the global breast cancer drug pipeline towards personalized medicine. Learn More

Other selected research from the 'Targeted' category:


Target Atlas in Oncology Drug Development: Major Tumor Types
This report is an open landscape of resources to build, fuel, and drive your scientific competitive vehicle for the advancement of cancer drugs. It will assist you in lead commercial analysis and product strategy thinking to build and nurture current and future portfolio of drug candidates and R&D alliances. Learn More


Cancer Antibodies: Competitive Positioning for Success
This report is written for you to identify your competition and understand which targeting strategies are at work within antibody drug development. It allows you to pin-point which competitors drugs’ clinical out-come may have bearing on your own drug development and who are developing sequels to blockbuster drugs. This report also helps you to locate white-spots in the competitive landscape, giving you little or no competition. Conversely it may reveal unexpected competition for you. Learn More